Appendix H. Table 4. Followup urine biochemical measures for allopurinol trials

| **Study** | **Treatment Groups, Urine Collection Method**  | **Calcium,****Oxalate,****Ca-Ox Product,** **Ca-Ox Supersaturation** | **Uric Acid, Uric-A Supersaturation** | **Phosphate, Ca-P Supersaturation** | **Citrate, Sodium, Magnesium** | **Potassium (K), Volume, pH** |
| --- | --- | --- | --- | --- | --- | --- |
| Ettinger, 198622 | A. Allopurinol 300 mg/d (n=36)B. Placebo (n=36)24 hour collectionStudy reported any data on participant compliance/adherence: Yes (tablet counts) | CALCIUMBaselineMean mg (SD): A (n=29) 238 (74)B (n=31) 211 (83)% hyperCa: NRF/u Time 1: 6 mo.Mean mg (SD): A (n=29) no signif changeB (n=31) no signif change% hyperCa: NROXALATEBaselineNMean (SD): NR% hyperOx: NRF/u Time 1: mo.NMean (SD): NR% hyperOx: NRCA-OX PRODUCTBaselineN | URIC ACIDBaselineMean mg (SD): A (n=29) 1017 (214)B (n=31) 935 (134)% hyperUA: NRF/u Time 1: 6 mo.Mean mg (SD): A (n=29) 660 (55)B (n=31) 885 (50)% hyperUA: NRURIC-A SUPERSATBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NR | PHOSPHATEBaselineNMean (SD): NR% hyperP: NRF/u Time 1: mo.NMean (SD): NR% hyperP: NRCA-P SUPERSATBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NR | CITRATEBaselineNMean (SD): NR% hypoCit: NRF/u Time 1: mo.NMean (SD): NR% hypoCit: NRSODIUMBaselineNMean (SD): NR% hyperNa: NRF/u Time 1: mo.NMean (SD): NR% hyperNa: NRMAGNESIUMBaselineNMean (SD): NR% hypoMg: NRF/u Time 1: mo.NMean (SD): NR% hypoMg: NR | POTASSIUMBaselineNMean (SD): NR% hypoK: NRF/u Time 1: mo.NMean (SD): NR% hypoK: NRVOLUMEBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NRpHBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NR |

| Appendix H. Table 4. Followup urine biochemical measures for allopurinol trials (continued) |
| --- |
| **Study** | **Treatment Groups, Urine Collection Method**  | **Calcium,****Oxalate,****Ca-Ox Product,** **Ca-Ox Supersaturation** | **Uric Acid, Uric-A Supersaturation** | **Phosphate, Ca-P Supersaturation** | **Citrate, Sodium, Magnesium** | **Potassium (K), Volume, pH** |
|  |  | Mean (SD): NRTime 1: mo.NMean (SD): NRCA-OX SUPERSATBaselineNMean (SD): NRTime 1: mo.NMean (SD): NR |  |  |  |  |
| Miano, 198523 | A. Allopurinol 300 mg/d (n=8)B. Placebo (n=7)24 hour collectionStudy reported any data on participant compliance/adherence: No | CALCIUMBaselineMean mg (SD): A (n=8) 203 (34)B (n=7) 218 (14)% hyperCa: NRF/u Time 1: 36 mo.Mean mg (SD): A (n=8) 210 (44)B (n=7) 218 (31)% hyperCa: NROXALATEBaselineNMean (SD): NR% hyperOx: NRF/u Time 1: mo.NMean (SD): NR% hyperOx: NRCA-OX PRODUCTBaselineNMean (SD): NRTime 1: mo.NMean (SD): NRCA-OX SUPERSATBaselineNMean (SD): NRTime 1: mo.NMean (SD): NR | URIC ACIDBaselineMean mg (SD): A (n=8) 513 (136)B (n=7) 421 (55)% hyperUA: NRF/u Time 1: 36 mo.Mean mg (SD): A (n=8) 444 (103)B (n=7) 482 (67)% hyperUA: NRURIC-A SUPERSATBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NR | PHOSPHATEBaselineNMean (SD): NR% hyperP: NRF/u Time 1: mo.NMean (SD): NR% hyperP: NRCA-P SUPERSATBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NR | CITRATEBaselineNMean (SD): NR% hypoCit: NRF/u Time 1: mo.NMean (SD): NR% hypoCit: NRSODIUMBaselineNMean (SD): NR% hyperNa: NRF/u Time 1: mo.NMean (SD): NR% hyperNa: NRMAGNESIUMBaselineNMean (SD): NR% hypoMg: NRF/u Time 1: mo.NMean (SD): NR% hypoMg: NR | POTASSIUMBaselineNMean (SD): NR% hypoK: NRF/u Time 1: mo.NMean (SD): NR% hypoK: NRVOLUMEBaselineMean mL (SD): A (n=8) 1314 (497)B (n=7) 1439 (368)F/u Time 1: 36 mo.Mean mL (SD): A (n=8) 1389 (312)B (n=7) 1653 (413)pHBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NR |

**Abbreviation:** NR = not reported